Verastem Oncology is a startup based in the United States, most recent round Series-c-plus, 2 tracked investors.
Based in the United States, Verastem Oncology is a startup founded in 2010. Its most recent tracked round is Series-c-plus. Brouky records 2 investors associated with the company.
Verastem Oncology is a biopharmaceutical company focused on developing and commercializing new medicines for cancer patients. Their lead product candidate, VS-6766, is a RAF/MEK inhibitor currently in clinical trials for various solid tumors.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.